FONR Quote, Financials, Valuation and Earnings

OncoCyte has a net margin of 7.87% compared to Fonar's net margin of -312.02%. Fonar's return on equity of 4.95% beat OncoCyte's return on equity of -693.81%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 58.3%. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than OncoCyte quarterly revenues of $2.1M. Fonar's net income of $2M is higher than OncoCyte's net income of -$6.7M. Notably, Fonar's price-to-earnings ratio is 11.22x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.81x versus 12.65x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 7.87% compared to Fonar's net margin of -209.38%. Fonar's return on equity of 4.95% beat ProPhase Labs's return on equity of -59.59%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3465.89%. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than ProPhase Labs quarterly revenues of $3.1M. Fonar's net income of $2M is higher than ProPhase Labs's net income of -$6.6M. Notably, Fonar's price-to-earnings ratio is 11.22x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.81x versus 1.17x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of 7.87% compared to Fonar's net margin of 6.16%. Fonar's return on equity of 4.95% beat Veracyte's return on equity of 2.85%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte has an analysts' consensus of $40.50 which suggests that it could grow by 38.7%. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are smaller than Veracyte quarterly revenues of $114.5M. Fonar's net income of $2M is lower than Veracyte's net income of $7M. Notably, Fonar's price-to-earnings ratio is 11.22x while Veracyte's PE ratio is 71.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.81x versus 4.98x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 7.87% compared to Fonar's net margin of -56.4%. Fonar's return on equity of 4.95% beat XWELL's return on equity of -71.82%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 669.23%. Given that XWELL has higher upside potential than Fonar, analysts believe XWELL is more attractive than Fonar.

Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than XWELL quarterly revenues of $8.4M. Fonar's net income of $2M is higher than XWELL's net income of -$4.8M. Notably, Fonar's price-to-earnings ratio is 11.22x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.81x versus 0.12x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.